Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc.

INBS
Intelligent Bio Solutions Inc.US flagNASDAQ Capital Market
2.23
USD
-0.07
- -
1.44MMarket Cap
Intelligent Bio Solutions Inc.
INBS
(NASDAQ Capital Market)

Recent

price

2.23

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
- -
- -
- -
- -
- -
- -
150.15
19.54
5.79
- -
3.72
Revenue per Share
- -
-1,067.26
-1,559.67
-743.89
-1,243.56
-1,359.42
-1,270.07
-63.77
-20.04
- -
-10.97
Basic EPS, GAAP
- -
-1,144.7
-1,185.63
-117.24
-1,996.2
-611.83
-941.64
-61.49
-18.79
- -
-10.63
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1,390.2
-3,078.12
-4,470.17
-1,225.07
2,658.57
1,067.85
195.74
24.1
4.09
1.9
1.9
Book Value per Share
-1,390.2
-3,078.12
-4,470.17
-1,225.07
2,658.57
1,067.85
-75.04
11.45
-1.08
0.93
0.93
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
1
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
1
3
3
4
4
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-671.23
-330.46
-342.64
-292.03
-290.68
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
1
1
1
1
Depreciation Expense
- -
-5
-7
-3
-7
-8
-11
-10
-11
-12
-12
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-845.89
-326.4
-346.23
-294.91
-294.91
Profit Margin (%)
-6
-3
-4
-5
15
6
-2
3
-1
2
2
Working Capital
- -
- -
- -
- -
- -
- -
1
- -
- -
2
2
LT Debt
-6
-3
-4
-5
15
7
4
8
3
5
5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-76.66
-203.99
-167.49
-186.64
-292.25
-292.25
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
2
3
Market Capitalization
12
7
7

Working Capital

FRC

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
12
10
7
Cash, Cash Equivalents & STI
1
7
4
Accounts Receivable, Net
- -
1
1
Inventories
1
1
- -
Total Current Liabilities
5
5
5
Payables & Accruals
4
4
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
1

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.86%
88.03%
Free Cash Flow
- -
18.2%
21.63%
Net Income, GAAP
- -
12.65%
17.62%
Sales/Revenue/Turnover
- -
- -
38.09%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
3
2025
1
1
1
1
3
2026
1
1
1
1
4

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-124.89
-20.74
-14.32
- -
-63.77
2025
-7.05
-4.96
-4.41
- -
-20.04
2026
-3.49
-2.82
-1.8
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Intelligent Bio Solutions Inc. operates as a medical technology enterprise, pioneering rapid, non-invasive testing solutions. The company's flagship offering is its Intelligent Fingerprinting Drug Screening System, which revolutionizes portable drug testing by analyzing sweat from fingertips. This innovative system quickly identifies recent use of substances like opiates, cocaine, methamphetamine, and cannabis, delivering results typically within ten minutes. This hygienic and cost-effective approach offers a significant alternative to traditional testing methods, eliminating biohazardous waste and privacy concerns while enhancing efficiency for users. The company strategically targets safety-critical industries such as construction, logistics, and manufacturing, along with drug treatment organizations and law enforcement. Its revenue model is largely driven by recurring sales of high-margin consumable cartridges, reflecting a "razor-razorblade" business strategy that has led to consistent growth. In pursuit of expanding its market presence, the company submitted a 510(k) premarket notification for its drug screening system to the U.S. Food and Drug Administration in late 2024, although the process has since evolved to a request for a new resubmission due to its novel nature. Intelligent Bio Solutions has achieved record quarterly revenues and significantly expanded its global footprint, now serving over 480 active customer accounts across more than 24 countries. Established in 2016 and headquartered in New York, New York, Intelligent Bio Solutions Inc., formerly known as GBS Inc. until its name change in October 2022, continues to advance its biosensor platform with potential for broader diagnostic applications across various medical indications.

Company News

  • Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission

  • Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules

  • BlackRock Inc. Invests $149.96 Million in Intelligent Bio Solutions Inc. $INBS

  • Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

  • Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action?

  • Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification

  • Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System

  • Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission

  • Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System

  • Comparing Eurofins Scient (OTCMKTS:ERFSF) & Intelligent Bio Solutions (NASDAQ:INBS)

  • Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry

  • Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market

  • Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

  • Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

  • Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

  • Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

  • Comparing Establishment Labs (NASDAQ:ESTA) & Intelligent Bio Solutions (NASDAQ:INBS)

  • Aeon Global Health (OTCMKTS:AGHC) vs. Intelligent Bio Solutions (NASDAQ:INBS) Head-To-Head Review

  • Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results

  • Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results